Merit Medical Systems Inc - MMSI STOCK NEWS

Merit Medical Systems (MMSI) reported Q2 2022 revenue of $295.0 million, reflecting a 5.2% increase from Q2 2021. Constant currency organic revenue grew 7.4%. The GAAP operating margin improved to 7.9% compared to 3.2% last year, with non-GAAP operating margin reaching 19.1%. GAAP EPS was $0.27, up from $0.09, and non-GAAP EPS rose to $0.73 from $0.62. Updated guidance for FY 2022 projects revenue between $1.123 billion to $1.135 billion, a 5% to 6% increase, with net income forecasted between $62.4 million to $68.3 million.

Merit Medical Systems has launched the Elation Pulmonary Balloon Dilator, the smallest configuration specifically designed for small airways in the U.S. market. This innovative product addresses a critical need in pulmonary care, enabling physicians to match balloon size to specific small airways, enhancing treatment options for patients with airway obstructions. The multi-stage balloon configuration also features a kink-resistant catheter, allowing for multiple dilations in one procedure. This development marks a significant advancement in minimally invasive treatments for lung conditions.

Merit Medical Systems, Inc. (NASDAQ: MMSI) will release its financial results for the quarter ending June 30, 2022, on July 27, 2022, after the market closes. An investor conference call is slated for the same day at 5:00 p.m. Eastern, providing insights into the company's performance. Merit specializes in proprietary disposable medical devices for various medical fields, employing approximately 6,500 people worldwide, with operations in multiple countries.

Merit Medical Systems (NASDAQ: MMSI) has initiated a prospective observational study in Canada to assess the effectiveness of the SCOUT® Radar Localization System in breast-conserving surgeries. The first patient has been enrolled in the study, which aims to include 500 patients and evaluate outcomes from the SCOUT procedure to surgery. The study is crucial for improving patient care, especially during the ongoing COVID-19 pandemic, and will examine safety, efficacy, and satisfaction levels among patients and clinicians.

Merit Medical Systems has launched the SCOUT Mini Reflector, an advanced device measuring 8 mm, which is 33% shorter than the standard SCOUT Reflector. This innovation enhances localization in challenging areas such as lymph nodes and is applicable during biopsy or pre-neoadjuvant chemotherapy. The SCOUT Mini offers superior directionality, improving accuracy to +/- 1 mm. It addresses over 300,000 new breast cancer cases diagnosed annually in the U.S., and supports multiple treatment scenarios. The SCOUT technology has been utilized in more than 275,000 procedures since 2015.

Merit Medical Systems (MMSI) has announced the successful enrollment of the first patient in the WRAP Registry Study, aimed at assessing the safety and efficacy of the WRAPSODY Cell-Impermeable Endoprosthesis for hemodialysis patients. This international study will enroll up to 500 patients facing vascular access issues due to stenosis or occlusion. It will monitor clinical outcomes over two years, providing critical real-world evidence that may enhance treatment options for over two million global dialysis patients suffering from vascular complications.

Merit Medical Systems reported Q1 2022 revenue of $275.4 million, up 10.6% from Q1 2021. Organic revenue grew 11.3%, while GAAP EPS was $0.18 compared to $0.19 in the prior year. Non-GAAP EPS increased to $0.53, slightly up from $0.52. The company anticipates a revenue increase of 4%-6% for 2022, expecting continued improvements in the operating environment. As of March 31, 2022, Merit had $56 million in cash and long-term debt of $253 million. The earnings call is scheduled for April 27, 2022.

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced the retirement of Chief Operating Officer Ronald A. Frost after over 30 years of service. Neil Peterson, a company veteran with 27 years of experience, has been appointed as the new COO. Peterson previously served as Vice President of Operations, overseeing operations in South Jordan, Utah. CEO Fred P. Lampropoulos praised Frost's contributions and expressed confidence in Peterson's capabilities to lead global operations effectively.